U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07109765) titled 'Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa' on July 31.
Brief Summary: This single-center, prospective, observational study aimed to evaluate the efficacy and safety of Secukinumab in treating moderate-to-severe hidradenitis suppurativa (HS). The study was conducted from June 1, 2025, to June 1, 2026, and all participants were treated at the Department of Dermatology, Peking Union Medical College Hospital. The study was approved by the Clinical and Research Ethics Committee of the Chinese Academy of Medical Sciences, Peking Union Medical College Hospital (Ethics Approval No. I-24PJ1844). All procedures invo...